CT引导下125I粒子植入联合化疗治疗中晚期周围型肺癌疗效评价

目的：评价CT引导下125 I粒子植入联合化疗治疗中晚期周围型肺癌疗效观察。方法：56例患者均有典型CT特征并经病理证实；并行放射粒子植入计划系统（TPS）计划，在CT导向下植入125I粒子；术后第3~7天开始行EP或GP方案化疗，共完成4个周期，同时记录不良反应。结果：56例患者均植入成功，追踪随访2~6个月，CR 9例（16.07%，9/56），PR 36例（64.28%，36/56），NC 7例（12.50%，7/56），总有效率80.35%（45/56）。追踪随访6~36个月，中位时间14.6月。生存率6个月91.10%（49/56），1年80.30%（45/56），2年60.70%（34/56），8例生存超过3年。结论：CT引导下125I粒子植入联合化疗治疗中晚期周围型肺癌有着疗效满意、安全易耐受和副反应小等优点，值得推广。

Evaluation of CT Guided Treatment of Advanced 125I Seed Implantation Combined with Chemotherapy in the Treatment of Peripheral Lung Cancer

Objective：To observe the curative effect evaluation of CT guided treatment of advanced 125I seed implantation combined with chemotherapy in the treatment of peripheral lung cancer.Method：56 cases of patients had typical CT features and confirmed by pathology.Parallel brachytherapy planning system（TPS）program,in the CT guided 125I seeds implantation.EP or GP chemotherapy started 3-7 d days after operation,a total of 4 cycles,and record adverse reactions.Result：56 cases of patients were implanted successfully,and were followed up for 2-6 months,9 cases was CR（16.07%,9/56）,36 cases was PR（64.28%,36/56）,7 cases was NC（12.5%,7/56）,the total efficiency was 80.35%（45/56）.Follow-up for 6-36 months,the median time of 14.6 months.Survival was 6 months（49/56,91.1%）,80.3%（45/56）1 years,2 years and 60.7%（34/56）, 8 cases survived over 3 years.Conclusion：CT guided 125I seeds implant combined with chemotherapy in the treatment of peripheral lung cancer has the advantage curative effect,safety tolerance and little side effect,is worth popularizing.